S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NASDAQ:RKDA

Arcadia Biosciences Stock Forecast, Price & News

$3.18
-0.15 (-4.50 %)
(As of 02/25/2021 04:50 PM ET)
Add
Compare
Today's Range
$3.12
Now: $3.18
$3.36
50-Day Range
$2.59
MA: $3.25
$5.69
52-Week Range
$2.30
Now: $3.18
$6.40
Volume749,740 shs
Average Volume2.31 million shs
Market Capitalization$67.82 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.62
Arcadia Biosciences, Inc., a consumer-driven agricultural technology company, engages in developing various crop productivity traits primarily in hemp, wheat, and soybean. The company's crop productivity traits are designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. Its products include GoodHemp, a commercial pipeline of non-GMO hemp seed varieties developed with modern crop innovation tools focused on genetic improvement of hemp; GoodWheat that redesigns wheat as a functional food adding value to the wheat supply chain by enabling a range of choices to meet consumer demands; nutritional oils; and HB4, a drought and herbicide tolerant soybean trait. The company has collaborations with Ardent Mills, LLC, Corteva AgriScience, and Arista Cereal Seeds Pty Ltd, and Bay State Milling Company. It operates in the United States, Canada, Africa, and India. The company was founded in 2002 and is headquartered in Davis, California.
Arcadia Biosciences logo

Industry, Sector and Symbol

Industry Agricultural production - crops
Sub-IndustryN/A
Current SymbolNASDAQ:RKDA
CUSIPN/A
Phone530-756-7077
Employees41
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 million
Book Value$0.96 per share

Profitability

Net Income$-28,810,000.00
Net Margins-1,499.85%

Miscellaneous

Market Cap$67.82 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.35 out of 5 stars

Basic Materials Sector

198th out of 823 stocks

Agricultural Production - Crops Industry

6th out of 21 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$3.18
-0.15 (-4.50 %)
(As of 02/25/2021 04:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RKDA News and Ratings via Email

Sign-up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

Is Arcadia Biosciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcadia Biosciences stock.
View analyst ratings for Arcadia Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Arcadia Biosciences?

Wall Street analysts have given Arcadia Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arcadia Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arcadia Biosciences?

Arcadia Biosciences saw a increase in short interest in January. As of January 29th, there was short interest totaling 1,960,000 shares, an increase of 851.9% from the January 14th total of 205,900 shares. Based on an average daily volume of 593,500 shares, the days-to-cover ratio is presently 3.3 days.
View Arcadia Biosciences' Short Interest
.

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Arcadia Biosciences
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Tuesday, November, 17th. The basic materials company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.06. The basic materials company earned $0.31 million during the quarter, compared to analysts' expectations of $0.97 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 177.69% and a negative net margin of 1,499.85%.
View Arcadia Biosciences' earnings history
.

How has Arcadia Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RKDA stock has increased by 0.3% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19
.

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for RKDA?

2 Wall Street analysts have issued 12 month price objectives for Arcadia Biosciences' shares. Their forecasts range from $6.00 to $16.00. On average, they expect Arcadia Biosciences' share price to reach $11.00 in the next year. This suggests a possible upside of 245.9% from the stock's current price.
View analysts' price targets for Arcadia Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the following people:
  • Mr. Matthew T. Plavan, Pres, CEO & Director (Age 57, Pay $476.04k)
  • Ms. Pamela Haley, CFO & Corp. Sec. (Age 50, Pay $268.47k)
  • Dr. Randall Shultz Ph.D., Chief Technology Officer
  • Mr. Christopher Williams-Campbell, Head of People
  • Ms. Gia Fazio Ph.D., Chief of Staff
  • Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 55)
  • Mr. Kevin Hodges, VP of Commercial Operations

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences CEO Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among Arcadia Biosciences' employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcadia Biosciences' key competitors?

What other stocks do shareholders of Arcadia Biosciences own?

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (1.18%), Wells Fargo & Company MN (0.29%) and LPL Financial LLC (0.25%). Company insiders that own Arcadia Biosciences stock include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan and Sarah Reiter.
View institutional ownership trends for Arcadia Biosciences
.

Which major investors are buying Arcadia Biosciences stock?

RKDA stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Wells Fargo & Company MN, and LPL Financial LLC. Company insiders that have bought Arcadia Biosciences stock in the last two years include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan, and Sarah Reiter.
View insider buying and selling activity for Arcadia Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $3.18.

How much money does Arcadia Biosciences make?

Arcadia Biosciences has a market capitalization of $67.82 million and generates $1.17 million in revenue each year. The basic materials company earns $-28,810,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis.

How many employees does Arcadia Biosciences have?

Arcadia Biosciences employs 41 workers across the globe.

What is Arcadia Biosciences' official website?

The official website for Arcadia Biosciences is www.arcadiabio.com.

Where are Arcadia Biosciences' headquarters?

Arcadia Biosciences is headquartered at 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.